For example, in FGFR inhibitor-resistant lung cancer cells, NRAS amplification and DUSP6 deletion resulted in mitogen-activated protein kinase (MAPK, i.e., ERK) reactivation [43]. This evidence concerns the gene NRAS and lung carcinoma.